New & Notable
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.
— BioPharma Dive
FDA moves toward real-time review of clinical trial data
Real-time clinical trials are a key step toward the FDA's "ultimate goal" of facilitating continuous trials, the federal agency says.
Obesity drugmakers chase weight loss. Biohaven is betting on muscles
With many pharma companies focused on developing drugs that shed pounds, Biohaven is digging its heels into a clinical program based on an experimental myostatin inhibitor that builds muscle.
— PharmaVoice
Boehringer's dual agonist obesity drug spurs up to 16.6% weight loss
Boehringer Ingelheim's dual-acting obesity shot led to weight loss comparable to Wegovy but could potentially help patients preserve more muscle mass.
5 notable pharma CEO pay hikes in 2025
— PharmaVoiceHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
AWS launches AI-driven tool to speed up early-stage antibody discovery
Amazon Web Services launches Amazon Bio Discovery, an AI-powered drug discovery tool to help speed up the development of antibody therapies.
-
FDA reminds sponsors, researchers to report clinical trial results
As part of its ongoing push for greater transparency, the FDA is seeking voluntary compliance from thousands of clinical trial sponsors and investigators, reminding them to publicly publish findings within one year of trial completion.
-
Amazon Pharmacy adds Lilly's obesity pill with same-day delivery
Amazon's pharmacy now sells Eli Lilly's recently approved weight loss pill at in-office kiosks and offers same-day delivery online.
-
TrumpRx adds more drugs as AbbVie, Genentech join self-pay platform
With the addition of AbbVie and Genentech this week, the number of Big Pharma companies now offering certain branded medications on TrumpRx has grown to 11.
-
Drug manufacturing deals move to Europe despite pharma tariffs
Last year marked the sharpest decline in U.S. contract manufacturing deals for FDA-approved drugs in half a decade, despite Trump's push for domestic onshoring, GlobalData finds.
-
Novo claims edge over Lilly's newly approved GLP-1 pill in cross study
Novo Nordisk is claiming the upper hand over Eli Lilly in the oral weight-loss drug market, saying its oral Wegovy topped Lilly's recently approved GLP-1 pill in a cross-trial comparison.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.